Post-spin Corteva offers a differentiated crop-protection franchise at a depressed multiple, with an $11 billion innovation pipeline and a $32.50 probability-weighted five-year value offset by material PFAS and pricing risks.
Overview
Corteva completed the tax-free spin-off of its Seed and Genetics business into Vylor Inc. on October 1, 2026, leaving New Corteva as an Indianapolis-based, pure-play crop-protection chemistry and biologicals company. It sells herbicides, fungicides, insecticides, and biologicals across approximately 110 countries, with proprietary formulations and global distribution supporting a top-tier market position. The strategic shift away from approximately $500 million of generic products has lifted differentiated products to about 65% of crop-protection sales, and an $11 billion pipeline includes 12 planned active-ingredient launches over the next decade. Q2 2026 sales were $6.379 billion, down 1% year over year and 2.9% below consensus, while Operating EPS of $2.30 beat estimates by 3.6%. First-half EBITDA rose 10% to $3.70 billion and margin expanded nearly 200 basis points to 32.8%; management raised 2026 EBITDA guidance to $4.1–$4.3 billion. Standalone shares traded at $13.30, around 8.5x–9.2x NTM EV/EBITDA, below a cited 10.7x historical Syngenta peer transaction average. **The core opportunity is a discounted, increasingly differentiated franchise**, with a $32.50 probability-weighted five-year value. Near-term catalysts include product adoption and standalone Q3 results on November 11, 2026; PFAS litigation and Latin American pricing are key risks.